Clinical Features and Prognostic Factors of 245 Portuguese Patients Hospitalized With COVID-19
Introduction Since the declaration of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in March 2020, Portugal was considered a role model with regards to the first COVID-19 wave. However, a third wave started in 2021 started, turning the country into the worst in the world regarding new infections and death rate per capita in the last weeks of January 2021. No significant data regarding the country's first wave of hospitalized patients have been published. Those data may help understand the differences over time regarding patients and the clinical approach to them. Herein, we present data of COVID-19 patients hospitalized at the main tertiary hospital of the second-most affected county at the time and identify risk factors associated with disease progression and outcomes.
Materials and methods We performed a prospective observational study of patients admitted with COVID-19 to a central hospital between March 20 and June 1, 2020. The primary endpoint of this study was 30-day mortality or the need for ventilatory support and the secondary outcomes were both outcomes individually.
Results 245 patients were included, with a median age of 79 years, 52% males. Hypertension (n = 172) and dyslipidemia (n = 114) were the most frequent comorbidities. Half of the patients (n = 121) were treated with hydroxychloroquine. The primary outcome occurred in 114 patients; mortality at 30 days was 35%. Age (OR 1.05; 1.02-1.07) and active cancer (OR 3.89; were associated with the primary outcome, with dyslipidemia being protective (OR 0.46; 0.25-0.80). Treatment with hydroxychloroquine or lopinavir/ritonavir was not associated with the main outcome. Patients who had been symptomatic for more than 7 days had lower mortality (OR 0.23; 0.09-0.63).
Discussion In the present study, age and cancer were associated with higher mortality, as noted in prior articles. The population had a higher median age than reported in previous studies, which may explain the increased mortality. The protective association of dyslipidemia was not previously described. This association was not related to statin intake.
Conclusion The reported high mortality of COVID-19 is rarely seen in other infectious diseases. Our elderly population probably reflects more reliably the incidence of COVID-19 in European countries with constricted age pyramids.
Additional Information Disclosures Human subjects: Consent was obtained or waived by all participants in this study. Comissão de Ética para a Saúde do Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE issued approval NA. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Barochiner, Martinez, Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: a systematic review and meta-analysis, J Clin Pharm Ther, doi:10.1111/jcpt.13246
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19 -preliminary report, N Engl J Med, doi:10.1056/NEJMoa2007764
Buitrago-Garcia, Egli-Gany, Counotte, Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis, PLoS Med, doi:10.1371/journal.pmed.1003346
Cai, Chen, Wang, Obesity and COVID-19 severity in a designated hospital in Shenzhen, China, Diabetes Care, doi:10.2337/dc20-0576
Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Cdc, People who are at higher risk for severe illness
Deng, Li, Zeng, Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study, J Infect, doi:10.1016/j.jinf.2020.03.002
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Levett, Raparelli, Mardigyan, Eisenberg, Cardiovascular pathophysiology, epidemiology, and treatment considerations of coronavirus disease, CJC Open, doi:10.1016/j.cjco.2020.09.003
Li, Huang, Zou, Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors and outcomes, J Med Virol, doi:10.1002/jmv.26424
Li, Xie, Lin, An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19, PREPPRINT, doi:10.1101/2020.03.19.20038984
Lim, Jeon, Shin, Case of the index patient who caused tertiary transmission of COVID-19 Infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR, J Korean Med Sci, doi:10.3346/jkms.2020.35.e79
Liu, Long, Xiong, Chen, Ma et al., Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: a rapid systematic review and meta-analysis, Clin Cardiol, doi:10.1002/clc.23421
Nasiri, Haddadi, Tahvildari, COVID-19 clinical characteristics, and sex-specific risk of mortality: systematic review and meta-analysis, Front Med, doi:10.3389/fmed.2020.00459
Pranata, Permana, Huang, The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.06.047
Prasad, Panhwar, Hendel, COVID-19 and the cardiovascular system: a review of current data, summary of best practices, outline of controversies, and illustrative case reports, Am Heart J, doi:10.1016/j.ahj.2020.06.009
Siddiqi, Mehra, COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal, J Heart Lung Transplant, doi:10.1016/j.healun.2020.03.012
Wang, Chen, Lu, Chen, Zhang, Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment, Biosci Trends, doi:10.5582/bst.2020.01030
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/s0140-6736(20)31022-9
Who, Weekly epidemiological update -2
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648